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CORRESPONDENCE
Re: Breast-Conserving Surgery
With or Without Radiotherapy:
Pooled-Analysis for Risks of
Ipsilateral Breast Tumor
Recurrence and Mortality
In a recent article in the Journal,
Vinh-Hung and Verschraegen (1) pro-
vided a valuable pooled analysis of
randomized trials of postoperative ra-
diotherapy after breast-conserving sur-
gery. They reported a small increase in
breast cancer mortality and a substan-
tial risk of local recurrence from the
omission of breast radiotherapy. These
important observations should not be
interpreted to imply that all patients
require breast radiotherapy after
breast-conserving surgery and appro-
priate systemic therapy. We believe,
however, that in contrast to younger
patients, there are insufficient data to
draw this conclusion in older patients.
Indeed, the U.S. National Institutes of
Health, in its 2000 consensus state-
ment for breast cancer (2), makes no
specific recommendation on adjuvant
therapy for patients aged 70 years or
older because of the paucity of data for
this group of patients. Of the 15 ran-
domized trials assessing the role of
breast radiotherapy or its omission in-
cluded in the pooled analysis by Vinh-
Hung (1), only three (Uppsala-Orebro,
Tokyo, and the Cancer and Leukemia
Group B [CALGB]) included patients
over age 70. In this older group of
patients, there are competing risks of
mortality from predominantly vascular
comorbidity. In addition, a body of
data from both randomized and non-
randomized trials suggests that the
risks of local recurrence decrease with
age (3). This observation reflects,
in part, the increasing proportion of
older patients with good prognostic
characteristics.
Large, adequately powered trials
with older patients are needed to as-
sess the role of breast radiotherapy in
local recurrence and breast cancer
mortality. The dramatic impact of the
competing risks of non– breast cancer
mortality in the elderly is shown in the
CALGB 9343 trial (4), cited in table 1
of Vinh-Hung and Verschraegen (1),
which randomly assigned patients with
T1, node-negative, ER-positive tumors
to breast radiotherapy or no further
treatment after breast-conserving ther-
apy and tamoxifen. Of the 39 deaths
among the 647 patients in the trial,
only one was due to breast cancer.
Ongoing trials, such as the Post-
operative Radiotherapy In Minimum-
risk Elderly (PRIME) trial (5), are ad-
dressing issues of local control,
morbidity, and quality of life in older,
low-risk patients to establish a firm
basis for the selection of patients for
radiotherapy in this age group. We feel
that until the results of randomized
trials focused on evaluating breast ra-
diotherapy in the elderly are available,
the role of breast radiotherapy in this
age group remains uncertain. For
many such women, their informed re-
cruitment into appropriately designed,
randomized, controlled trials may be
the most ethical way of determining
treatment.
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RESPONSE
Kunkler et al. address an important
issue: whether or not to continue ran-
domized trials of postoperative radio-
therapy after breast-conserving surgery
in selected patient subgroups such as
those in the Scottish Post-operative Ra-
diotherapy In Minimum-risk Elderly II
(PRIME II) and the Italian RT 55-75
trials (1). We welcome the opportunity
to analyze the additional data that the
PRIME II and the RT 55-75 trials will
provide because we think these data will
help patients make the best treatment
choices.
In 2003, the updated report (2) from
the 2001 Cancer and Leukemia Group B
(CALGB) 9343 trial (3) provided in-
sight into several age-related issues. One
issue is that the extreme difficulty in
following up older patients may have
led earlier studies to mistakenly con-
clude a lower risk of recurrence. The
updated report revealed substantially
improved registration of deaths and re-
currences—55 deaths were reported (30
deaths with no radiotherapy, 25 deaths
with radiotherapy, and a statistically
nonsignificant 19% excess relative risk
of mortality from omitting radiother-
apy). The updated report also showed
statistically significantly poorer in-
breast and poorer locoregional recur-
rence-free survivals in the absence of
radiotherapy (2).
Although elderly patients are under-
represented in clinical trials, the rela-
tionship between age and survival in
breast cancer is now well established.
All large studies concur that the effect of
age is biphasic: high mortality in
younger women, lowest in menopausal
women, and then increasing again with
age (Tai P: personal communication).
To provide a concrete representation of
the biphasic relationship and to obtain
quantitative estimates of the risks asso-
ciated with age, consider a cohort of
low-risk patients who have a primary
Journal of the National Cancer Institute, Vol. 96, No. 16, August 18, 2004 CORRESPONDENCE 1255
breast carcinoma 2 cm or less in diam-
eter, and a status of pN0 (axillary dis-
section) selected from the Surveillance,
Epidemiology, and End Results (SEER)
database, for diagnostic years 1988 –
1997 (4). Figure 1 shows counts and
rates of death in this cohort as a func-
tion of age. The average follow-up
was 7.8 years. Despite the short fol-
low-up period and the overall low
breast cancer–specific death rate, the
biphasic shape is immediately appar-
ent: high breast cancer death rates in
patients younger than 50 years and a
small but steady increase in patients
aged 50 years or older (Fig. 1, D). This
biphasic relationship clarifies how
breast cancer can be misperceived as
being indolent in older patients. Group
comparisons indicate that postmeno-
pausal patients, as a group, have a
lower risk of breast cancer death than
younger premenopausal patients (Fig.
1, D). But by each successive year of
age within their group, the older post-
menopausal patients have a greater
risk of dying of breast cancer than do
younger postmenopausal patients (Fig.
1, D), which shows that older age is
not associated with lower risk.
Should we infer from the unremitting
risk that all patients, regardless of age,
should receive adjuvant radiotherapy?
Kunkler et al. draw attention to the im-
portance of competing risks of death.
Figure 1, E, shows an exponential in-
crease of non–breast cancer deaths with
age. Figure 1, F, shows the correspond-
ing odds of non–breast cancer death. At
age 60 years, the odds of death from
breast cancer versus other causes are
1:2.5. At age 65 years, the odds are still
substantial: 1:3.5. At age 70 years, the
odds are 1:5. At age 80 years, the odds
are 1:10. Considering mortality only,
these odds suggest that it is reasonable
to propose that low-risk older patients
participate in the PRIME II trial. But
taking local recurrences into account, if
patients are considered fit for surgery,
then it is unclear why they should be
denied the chance to have radiotherapy
to reduce their risk of recurrence. The
evidence of risk reduction is strong, and
improvements that will benefit low-risk
and fragile patients are within reach (5).
Shouldn’t the priority be to enroll these
patients in trials of alternatives to con-
ventional radiotherapy, whether it be
short-course (6) or intra-operative radio-
therapy (7)?
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Fig. 1. Mortality as a func-
tion of age for low-risk
breast cancer patients with
the following characteris-
tics: primary breast carci-
noma 2 cm, pN0, exclud-
ing high-grade and estrogen
receptor–negative tumors,
from the Surveillance, Epi-
demiology, and End Results
(SEER) Program 2004 data-
base (9 registries), diagnos-
tic years 1988–1997 (4), ir-
respective of type of
surgery or radiotherapy, age
25 to 95 years; N  32 045.
A) Counts of breast cancer–
specific deaths. B) Counts
of deaths from other causes.
C) Total incidence counts.
D) Crude rates of death
from breast cancer. E)
Crude rates of death from
other causes. F) Odds of
death from other causes
versus from breast cancer,
based on a log scale (empir-
ical logistic transform).
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